# TART - Troglitazone Atherosclerosis Regression Trial

> **NCT00116545** · PHASE2,PHASE3 · COMPLETED · sponsor: **Parke-Davis** · enrollment: 288 (—)

## Conditions studied

- Atherosclerosis
- Diabetes Mellitus

## Interventions

- **DRUG:** troglitazone

## Key facts

- **NCT ID:** NCT00116545
- **Lead sponsor:** Parke-Davis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** 2000-04
- **Final completion:** 2000-04
- **Target enrollment:** 288 (—)
- **Last updated:** 2009-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116545, "TART - Troglitazone Atherosclerosis Regression Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00116545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*